Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review

Table 2 Study outcomes of TNBC patients treated with NCCN-recommended (v1.2019) monotherapy in trials published since 2016

Author	Study description	Treatment	Patient population	% 1L	% 2L	N	ORR %	PFS months	OS months	% TNBC patients
Tutt et al. [19]	Phase III TNT	Car	2L+ mTNBC		100	59	31.4	3.1	12.4	100
Tutt et al. [19]	Phase III TNT	Doc				64	34.0	4.5	12.3	100
Kim et al. [15] and Dent et al. [14]	Phase II LOTUS	Pac+Ipatasertib	1L mTNBC	100		62	NR	6.2	NR	100
Kim et al. [15] and Dent et al. [14]	Phase II LOTUS	Pac	1L mTNBC	100		62	NR	4.9	NR	100
Schmid et al. [10]	Phase III IMpassion130	Atezolizumab plus nab-paclitaxel	1L mTNBC	100		451	NR	7.2	21.3	100
Schmid et al. [10]	Phase III IMpassion130	nab-paclitaxel	1L mTNBC	100		451	NR	5.5	17.6	100
Robson et al. [17, 18]	Phase III OLYMPIAD	Olaparib	1L–2L mBC		100	205	NR	7.0	19.3	49.8
Robson et al. [17, 18]	Phase III OLYMPIAD	Physician’s-Choice	1L–2L mBC			97	NR	4.2	17.1	49.5
Litton et al. [16]	Phase III EMBRACA	Talazoparib	2L+ locally advanced BC		100	287	62.6	8.6	NR	45.3
Litton et al. [16]	Phase III EMBRACA	Physician’s-Choice	2L+ locally advanced BC			144	27.2	5.6	NR	41.7

1L first-line, 2L second-line, BC breast cancer, Car carboplatin, Doc docetaxel, mTNBC metastatic triple-negative breast cancer, N/R not reported, ORR objective response rate, OS overall survival, Pac paclitaxel, PFS progression-free survival, TNBC triple-negative breast cancer

ISSN: 1465-542X